Working… Menu

The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM) (PORYOU)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03242460
Recruitment Status : Completed
First Posted : August 8, 2017
Last Update Posted : February 20, 2020
Information provided by (Responsible Party):
Ho Sup Lee, Kosin University Gospel Hospital

Brief Summary:
In Korea, VMP is most commonly used as frontline treatment in patients with newly diagnosed MM who were ineligible for high-dose therapy. Recently National Insurance began to reimburse the second-line LD when the bortezomib-containing treatment failed to salvage the patients. Patients who have relapsed MM after exposure to the above agents and have progressive disease have a short life expectancy. Third-line therapy is needed for retrieving the patients hereafter. And substantial proportion of patients will attain an advanced age. To examine if time to disease progression is maintained and tolerability is improved with lower dexamethasone dose, the dose of dexamethasone is reduced when at least a minimal response is achieved after 3 months of treatment with the initial dose. Three months later (6 months after the initial treatment), the response remains in stable disease, 2nd dose reduction (dexamethasone 10mg or prednisone 50mg) will be carried out.

Condition or disease Intervention/treatment Phase
Relapsed and/or refractorY Multiple Myeloma Drug: Pomalidomide 4 MG Drug: Dexamethasone 20mg Drug: Cyclophosphamide 400mg Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 55 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: the transplant-ineligible patients with Relapsed and/or refractorY multiple myeloma (MM) who had lenalidomide+dexamethasone (LD) following frontline bortezomib combined chemotherapy
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM) Who Had Lenalidomide Plus Dexamethasone (LD) Following Frontline Bortezomib Combined Chemotherapy, Open-labeled, Multicenter Phase II Study
Study Start Date : May 12, 2015
Actual Primary Completion Date : April 24, 2019
Actual Study Completion Date : May 2, 2019

Arm Intervention/treatment
Experimental: Pomalidomide, Dexamethasone, Cyclophosphamide
Pomalidomide 4mg Days 1-21 Dexamethasone 20mg Days 1, 8, 15, 22 Cyclophosphamide 400mg Days 1, 8, 15
Drug: Pomalidomide 4 MG
Pomalidomide 4mg Days 1-21
Other Name: pomalyst

Drug: Dexamethasone 20mg
Dexamethasone 20mg Days 1, 8, 15, 22

Drug: Cyclophosphamide 400mg
Cyclophosphamide 400mg Days 1, 8, 15

Primary Outcome Measures :
  1. Median Progression-free Survival (PFS) [ Time Frame: 2 years follow up ]
    Kaplan-Meier method

Secondary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: 2 years follow up ]
    International Myeloma Working Group,( IMWG)

  2. Overall survival (OS) [ Time Frame: 2 years follow up ]
    Kaplan-Meier method

  3. Safety evaluations assessed using Common Terminology Criteria for Adverse Events v4.0 [ Time Frame: 2 years follow up ]
    Common Terminology Criteria for Adverse Events v4.0

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have evaluable multiple myeloma with at least one of the following (within 21 days of starting treatment)

    • Serum M-protein ≥ 0.5g/dL, or
    • In subjects without detectable serum M-protein, Urine M-protein ≥ 200mg/24 hour, or serum free light chai (sFLC) > 100mg/L (involved light chain) and an abnormal kappa/Lambda ratio
  • Patients were ineligible for autologous stem cell transplantation
  • Must be relapse refractory to initial therapy with bortezomib, melphalan and prednison and then lenalidomide plus dexamethasone.
  • Refractoriness is defined as disease progression on treatment or progression within 6 months after the last dose of a given therapy. Relapse is defined according to the criteria of IMWG
  • Males and females ≥ 18 years of age or > country's legal age for adult consent
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
  • Patients must meet the following clinical laboratory criteria with 21 days of starting treatment:

    • Absolute neutrophil count (ANC) ≥ 1,000/mm3 and platelet ≥ 50,000/mm3 (≥ 30,000/mm3 if myeloma involvement in the bone marrow is >50%)
    • Total bilirubin ≤ 1.5 x the upper limit of the normal range (ULN). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN.
    • Calculated creatinine clearance ≥ 30mL/min or creatinine < 3mg/dL.
  • Written informed consent in accordance with federal, local and institutional guidelines

Exclusion Criteria:

  • Female patients who are lactating or pregnant
  • Multiple Myeloma of IgM subtype
  • Glucocorticoid therapy (prednisolone > 30mg/day or equivalent) within 14 days prior to informed consent obtained
  • POEMS syndrome, plasma cell leukemia or circulating plasma cells ≥ 2 x 109/L, Waldenstrom's Macroglobulinaemia, or Patients with known amyloidosis
  • Peripheral neuropathy grade > 2
  • Chemotherapy with approved or investigation anticancer therapeutics within 21 days prior to starting pomalidomide treatment
  • Focal radiation therapy within 7 days prior to start of pomalidomide. Radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to start of pomalidomide
  • Immunotherapy (excluding steroids) 21 days prior to start of pomalidomide
  • Major surgery (excluding kyphoplasty) within 28 days prior to start of pomalidomide
  • Active congestive heart failure (New York Heart Association [NYHA] Class III or IV), symptomatic ischaemia, or conduction abnormalities uncontrolled by conventional intervention. Myocardial infarction within 4 months prior to informed consent obtained
  • Known HIV seropositive, hepatitis C infection, and/or hepatitis B (except for patients with hepatitis B surface antigen or core antibody receiving and responding to antiviral therapy directed at hepatitis B: these patients are allowed)
  • Second malignancy within the past 3 years except:

    • Adequately treated basal cell or squamous cell skin cancer
    • Carcinoma in situ of the cervix
    • Breast carcinoma in situ with full surgical resection
  • Patients with steroid or lenalidomide hypersensitivity
  • Patients with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to starting pomalidomide treatment
  • Any clinically significant medical disease or psychiatric condition that, in the investigator's opinion, may interfere with protocol adherence or a patient's ability to give informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03242460

Layout table for location information
Korea, Republic of
Catholic university of korea, Seoul ST. Mary's Hospital.
Seoul, Korea, Republic of
Sponsors and Collaborators
Kosin University Gospel Hospital
Layout table for additonal information
Responsible Party: Ho Sup Lee, MD, PhD. associate professor, Division of hematology-Oncology, Kosin University Gospel Hospital Identifier: NCT03242460    
Other Study ID Numbers: PORYOU
First Posted: August 8, 2017    Key Record Dates
Last Update Posted: February 20, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: KMMWP

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents